Skip to content
10-Q

Quarterly Report

CNBX PHARMACEUTICALS INC. CNBX

0001683168-23-004890

← back to feed
Filed
Jul 14, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Jul 14, 2023 17.03M sh
Cash And Equivalents Q3 2023 · May 31, 2023 $44.15K
Cash And Equivalents Q3 2023 · Aug 31, 2022 $117.52K
Current Liabilities Q3 2023 · May 31, 2023 $2.57M
Current Liabilities Q3 2023 · Aug 31, 2022 $2.44M
Current Assets Q3 2023 · May 31, 2023 $348.8K
Current Assets Q3 2023 · Aug 31, 2022 $198.29K
Total Assets Q3 2023 · May 31, 2023 $662.02K
Total Assets Q3 2023 · Aug 31, 2022 $811.17K
Shares Diluted Q3 2023 · May 31, 2022 1.24M sh
Shares Diluted Q3 2023 · May 31, 2022 1.22M sh
Operating Cash Flow Q3 2023 · May 31, 2022 −$1.53M
Stockholders Equity Q3 2023 · May 31, 2022 −$1.18M
Stockholders Equity Q3 2023 · Feb 28, 2022 −$648.03K
Stockholders Equity Q3 2023 · Aug 31, 2021 $1.81M
Eps Diluted Q3 2023 · May 31, 2022 −$0.05
Eps Diluted Q3 2023 · May 31, 2022 −$2.65
Eps Basic Q3 2023 · May 31, 2022 −$0.05
Eps Basic Q3 2023 · May 31, 2022 −$2.65
Sga Expense Q3 2023 · May 31, 2022 $385.95K
Sga Expense Q3 2023 · May 31, 2022 $1.46M
Rd Expense Q3 2023 · May 31, 2022 $249.06K
Rd Expense Q3 2023 · May 31, 2022 $1.02M
Net Income Q3 2023 · May 31, 2022 −$681.65K
Net Income Q3 2023 · May 31, 2022 −$3.24M
Operating Income Q3 2023 · May 31, 2022 −$635.01K
Operating Income Q3 2023 · May 31, 2022 −$2.48M
Revenue Q3 2023 · May 31, 2022 $0
Revenue Q3 2023 · May 31, 2022 $0